Catastrophic Antiphospholipid Syndrome: Candidate Therapies for a Potentially Lethal Disease

Annual Review of Medicine

Volumn 68, Issue , 2017, Pages 287-296

  Unlu, Ozan ^a   Erkan, Doruk ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Antiphospholipid syndrome; CAPS; Defibrotide; Eculizumab; Hydroxychloroquine; Rituximab; Sirolimus

Indexed keywords

ANTICOAGULANT AGENT; CORTICOSTEROID; DEFIBROTIDE; ECULIZUMAB; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; RAPAMYCIN; RITUXIMAB; ANTIRHEUMATIC AGENT; ANTITHROMBOCYTIC AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; POLYDEOXYRIBONUCLEOTIDE;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME; COMORBIDITY; DISEASE CLASSIFICATION; DISEASE COURSE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PLASMA EXCHANGE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOSIS; THROMBOTIC STORM; THROMBOTIC THROMBOCYTOPENIC PURPURA; PATIENT CARE; TERMINAL DISEASE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIPHOSPHOLIPID SYNDROME; ANTIRHEUMATIC AGENTS; CATASTROPHIC ILLNESS; HUMANS; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENTS; PATIENT CARE TEAM; PLASMA EXCHANGE; PLATELET AGGREGATION INHIBITORS; POLYDEOXYRIBONUCLEOTIDES; RITUXIMAB; SIROLIMUS;

EID: 85009949475     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-042915-102529     Document Type: Review

References (62)

1. Miyakis S, Lockshin MD, Atsumi T, et al. 2006. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4:295-306
2. Erkan D, LockshinMD. 2010. Non-criteria manifestations of antiphospholipid syndrome. Lupus 19:424-27
3. Asherson RA. 1992. The catastrophic antiphospholipid syndrome. J. Rheumatol. 19:508-12
4. Piette JC, Cervera R, Levy RA, et al. 2003. The catastrophic antiphospholipid syndrome-Asherson's syndrome. Ann. Med. Interne (Paris) 154:195-96
5. AshersonRA, CerveraR, deGroot PG, et al. 2003. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12:530-34
6. Aguiar CL, Erkan D. 2013. Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease. Ther. Adv. Musculoskelet. Dis. 5:305-14
7. Cervera R, Rodriguez-Pinto I, Colafrancesco S, et al. 2014. 14th International Congress on Antiphospholipid Antibodies: task force report on catastrophic antiphospholipid syndrome. Autoimmun. Rev. 13:699-707
8. Erkan D, Espinosa G, Cervera R. 2010. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun. Rev. 10:74-79
9. Ortel TL, Erkan D, Kitchens CS. 2015. How I treat catastrophic thrombotic syndromes. Blood 126:1285-93
10. Ortel TL, Kitchens CS, Erkan D, et al. 2012. Clinical causes and treatment of the thrombotic storm. Expert Rev. Hematol. 5:653-59
11. Cervera R. 2012. CAPS registry. Lupus 21:755-57
12. Girardi G, Redecha P, Salmon JE. 2004. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat. Med. 10:1222-26
13. Asherson RA, Cervera R, Merrill JT, Erkan D. 2008. Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment. Semin. Thromb. Hemost. 34:256-66
14. Erkan D, Cervera R, Asherson RA. 2003. Catastrophic antiphospholipid syndrome:Where do we stand Arthritis Rheumatol. 48:3320-27
15. Bayraktar UD, Erkan D, Bucciarelli S, et al. 2007. The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J. Rheumatol. 34:346-52
16. ErkanD, Aguiar CL, Andrade D, et al. 2014. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun. Rev. 13:685-96
17. Cervera R, Asherson RA. 2004. Multiorgan failure due to rapid occlusive vascular disease in antiphospholipid syndrome: the 'catastrophic' antiphospholipid syndrome. APLAR J. Rheumatol. 7:254-62
18. Erkan D, Salmon JE. 2016. The role of complement inhibition in thrombotic angiopathies and antiphospholipid syndrome. Turk. J. Haematol. 33:1-7
19. Edwards MH, Pierangeli S, Liu X, et al. 1997. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 96:4380-84
20. Rand JH, Wu XX, Quinn AS, et al. 2008. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 112:1687-95
21. Rand JH, Wu XX, Quinn AS, et al. 2010. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 115:2292-99
22. Wu XX, Guller S, Rand JH. 2011. Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression. Am. J. Obstet. Gynecol. 205:576-714
23. Sacre K, Criswell LA, McCune JM. 2012. Hydroxychloroquine is associated with impaired interferonalpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res. Ther. 14:R155
24. Johnson R, Charnley J. 1979. Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty. Clin. Orthop. Relat. Res. 144:174-77
25. Wallace DJ. 1987. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus Arthritis Rheumatol. 30:1435-36
26. Petri M, Law G, Fang H, Magder L. 2013. Hydroxychloroquine reduces thrombosis (both arterial and venous) in systemic lupus erythematosus, but only in antiphospholipid positive patients. Proc. Int. Congr. Antiphospholipid Antibodies, 14th, Rio de Janeiro, Brazil, pp. 18-21
27. Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. 2009. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheumatol. 61:29-36
28. Buch MH, Smolen JS, Betteridge N, et al. 2011. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70:909-20
29. Khattri S, Zandman-Goddard G, Peeva E. 2012. B-cell directed therapies in antiphospholipid antibody syndrome-new directions based on murine and human data. Autoimmun. Rev. 11:717-22
30. Youinou P, Renaudineau Y. 2004. The antiphospholipid syndrome as a model for B cell-induced autoimmune diseases. Thromb. Res. 114:363-69
31. Kahn P, Ramanujam M, Bethunaickan R, et al. 2008. Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis Rheumatol. 58:2824-34
32. Akkerman A, Huang W, Wang X, et al. 2004. CTLA4Ig prevents initiation but not evolution of antiphospholipid syndrome in NZW/BXSB mice. Autoimmunity 37:445-51
33. Erdozain JG, Ruiz-Irastorza G, Egurbide MV, Aguirre C. 2004. Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome. Haematologica 89:Ecr34
34. Erre GL, Pardini S, Faedda R, Passiu G. 2008. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus 17:50-55
35. Kumar D, Roubey RA. 2010. Use of rituximab in the antiphospholipid syndrome. Curr. Rheumatol. Rep. 12:40-44
36. Rubenstein E, Arkfeld DG, Metyas S, et al. 2006. Rituximab treatment for resistant antiphospholipid syndrome. J. Rheumatol. 33:355-57
37. Tenedios F, Erkan D, Lockshin M. 2005. Rituximab in the primary antiphospholipid syndrome (PAPS). Arthritis Rheumatol. 52:4078
38. Aguiar CL, Erkan D. 2013. The effect of rituximab on the antiphospholipid antibody profile. Proc. APLALACA (Abstr. ), Int. Congr. Antiphospholipid Antibodies, 14th, and Latin Am. Congr. Autoimmun., 4th, Sep. 18-21, Rio de Janeiro, Brazil
39. Ames PR, Tommasino C, Fossati G, et al. 2007. Limited effect of rituximab on thrombocytopaenia and anticardiolipin antibodies in a patient with primary antiphospholipid syndrome. Ann. Hematol. 86:227-28
40. Tommasino C, Fossati G, Saulino A, et al. 2004. Short-term lack of efficacy of rituximab in a thrombocytopaenic patient with primary antiphospholipid syndrome. Thromb. Res. 114:652 (Abstr. )
41. Sciascia S, Naretto C, Rossi D, et al. 2011. Treatment-induced downregulation of antiphospholipid antibodies: effect of rituximab alone on clinical and laboratory features of antiphospholipid syndrome. Lupus 20:1106-8
42. Trappe R, Loew A, Thuss-Patience P, et al. 2006. Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab-monitoring of antiphospholipid and anti-GP antibodies: a case report. Ann. Hematol. 85:134-35
43. Costa R, Fazal S, Kaplan RB, et al. 2013. Successful plasma exchange combined with rituximab therapy in aggressive APS-related cutaneous necrosis. Clin. Rheumatol. 32(Suppl. 1):S79-S82
44. Tsagalis G, Psimenou E, Nakopoulou L, Laggouranis A. 2011.combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation. Artif. Organs 35:420-25
45. Ehresmann SAD, Shinada S, et al. 2004. A novel therapeutic approach for catastrophic antiphospholipid syndrome (CAPS) when conventional therapy with anticoagulants and steroids were unsuccessful. Ann. Rheum. Dis. 64(Suppl. ):FR10278 (Abstr. )
46. Berman H, Rodriguez-Pinto I, Cervera R, et al. 2013. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun. Rev. 12:1085-90
47. Erkan D, Vega J, Ramon G, et al. 2013. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheumatol. 65:464-71
48. CanaudG, Kamar N, AnglicheauD, et al. 2013. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am. J. Transplant. 13:2179-85
49. Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. 2007. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 109:422-30
50. Peerschke EI, YinW, Ghebrehiwet B. 2010.complement activation on platelets: implications for vascular inflammation and thrombosis. Mol. Immunol. 47:2170-75
51. CanaudG, Bienaime F, Tabarin F, et al. 2014. Inhibition of themTORC pathway in the antiphospholipid syndrome. N. Engl. J. Med. 371:303-12
52. Pierangeli SS, Girardi G, Vega-Ostertag M, et al. 2005. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheumatol. 52:2120-24
53. Oku K, Amengual O, Atsumi T. 2012. Pathophysiology of thrombosis and pregnancy morbidity in the antiphospholipid syndrome. Eur. J. Clin. Investig. 42:1126-35
54. Devreese KM, HoylaertsMF. 2010. Is there an association between complement activation and antiphospholipid antibody-related thrombosis Thromb. Haemost. 104:1279-81
55. Zikos TA, Sokolove J, Ahuja N, Berube C. 2015. Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome. J. Clin. Rheumatol. 21:311-13
56. Sehgal SN. 2003. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant. Proc. 35:7s-14s
57. Rubbia-Brandt L. 2010. Sinusoidal obstruction syndrome. Clin. Liver Dis. 14:651-68
58. Pescador R, Porta R, Ferro L. 1996. An integrated view of the activities of defibrotide. Semin. Thromb. Hemost. 22(Suppl. 1):71-75
59. Richardson PG, Elias AD, Krishnan A, et al. 1998. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 92:737-44
60. Falanga A, Vignoli A, Marchetti M, Barbui T. 2003. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia 17:1636-42
61. Burcoglu-O'Ral A, Erkan D, Asherson R. 2002. Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. J. Rheumatol. 29:2006-11
62. Wilson WA, Gharavi AE, Koike T, et al. 1999. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheumatol. 42:1309-11